Can patients with insulin-dependent type 2 diabetes and low endogenous insulin production due to beta cell deficiency be prescribed GLP1 RAs to improve their glycemic control and potentially decrease liver fat? What are your thoughts on using GLP1 RA therapy as an adjunctive treatment option?

Share your opinion in the comments below.